Quantitative determination of pidotimod in human plasma by liquid chromatography tandem mass spectrometry: Application to a bioequivalence study

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 2, 2012, Pages 99-104

  Lou, H G ^a   Ruan, Z R ^a   Jiang, B ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

bioequivalence; CAS 121808 62 6; LC MS MS; pharmacokinetics; pidotimod

Indexed keywords

PIDOTIMOD; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; IMMUNOLOGICAL ADJUVANT; PYROGLUTAMIC ACID; THIAZOLIDINE DERIVATIVE;

ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; AREA UNDER THE CURVE; ASIAN; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROSPRAY MASS SPECTROMETRY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARD;

ADJUVANTS, IMMUNOLOGIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; INDICATORS AND REAGENTS; PYRROLIDONECARBOXYLIC ACID; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; THIAZOLIDINES;

EID: 84859926741     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297983     Document Type: Article

References (10)

1. Maillard F. Pidotimod, A new biological response modifier, Introduction. Arzneimittelforschung: 1994; 44 12A 1399 13401
2. Migliorati G, Nicoletti I, Riccardi C. Arzneimittelforschung. Immunomodulating activity of pidotimod: 1994; 44 12A 1421 1424
3. Riboldi P, Gerosa M, Meroni P L. Int J Immunopathol Pharmacol: 2009; 22 255 262
4. Coppi G, Barchielli M. Simple high-performance liquid chromatographic method for the determination of PGT/1A, a new immunostimulating drug, in biological fluids. J chromatogr: 1991; 563 02 385 391
5. Dal Bo L, Broccali G P, Silingardi S et al. A new HPLC method for pidotimod plasma levels determination. Boll Chim Farm: 1993; 132 04 126 128 (Pubitemid 23191870)
6. Mailland F, Coppi G, Silingardi S. Pharmacokinetics and oral bioavailability of pidotimod in humans. Arzneimittelforschung: 1994; 44 12A 1465 1469
7. Wei Y, Zhang M Y, Wang K S et al. Study on bioequivanlence of pidotimod granules. Chin J New Drugs: 2003; 12 461 463
8. Dong H J, Li J C, Gao S et al. Pharmacokinetics and Bioequivalence of Pidotimod Dried-Suspension in Healthy Volunteer. Chin Pharm: 2008; 35 19 2750 2752
9. Zhang Y, Xiong Z L, Qin F et al. High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study. J Chromatogr B: 2009; 877 2566 2570
10. FDA: Guidance for Industry: Bioanalytical Method Validation U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2001. http://www.fda.gov/cder/guidance/ index. htm/